Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients.
Sixteen patients with advanced (International Federation of Gynecology and Obstetrics stage III and IV) adenocarcinoma of the endometrium were treated with twelve 28-day cycles of doxorubicin and cisplatin. Response was achieved in 92% of patients (11 responses among 12 patients) who had received no prior chemotherapy and in 50% (two responses among four patients) of previously treated patients. Median survival was 10 months. Doxorubicin and cisplatin were readily administered on an outpatient basis with comparatively low major toxic effects, primarily hematologic, renal, and gastrointestinal. These results indicate that doxorubicin and cisplatin combination therapy is effective with acceptable toxicity in patients with advanced endometrial carcinoma.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001769:Blood / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D004064:Digestive System / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008875:Middle Aged; D009367:Neoplasm Staging; D014594:Uterine Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D002945:Cisplatin